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I Weng Lao1,2, Lin Yu1,2 and Jian Wang1,2*Abstract
Background: We describe a case of malignant perivascular epithelial cell tumor (PEComa) arising primarily in the
distal left femur of a 47-year-old male.
Case presentation: The patient presented with pain accompanied by progressive swelling of his left thigh.
Computed tomography (CT) scan and magnetic resonance imaging (MRI) revealed an osteolytic lesion. Curettage of
the lesion was reported as a clear cell tumor with recommendation for exclusion of a metastatic clear cell
carcinoma. However, thorough examinations did not find any primary site elsewhere, apart from the presence of
bilateral pulmonary metastases. Evaluation of the submitted H & E slides identified a malignant PEComa which was
further confirmed by subsequent immunohistochemical study.
Conclusions: The occurrence of PEComa as a primary bone lesion is extremely rare. We present here a malignant
PEComa of the distal left femur, and summarize the clinicopathological characteristics of this rare entity with
literature review.
Virtual slides: The virtual slide (s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5729035221600545.
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Perivascular epithelioid cell tumor (PEComa) represents a
family of closely related entities showing both melanocytic
and myoid differentiation, including angiomyolipoma,
lymphangioleiomyomatosis, clear-cell ‘sugar’ tumor of the
lung, and neoplasms arising in a wide variety of locations
including skin, soft tissue and visceral organs called
PEComa not otherwise specified (PEComa-NOS) [1].
PEComa manifesting as a primary bone lesion is extremely
rare. To date, only 10 convincing cases of primary bone
origin have been reported in the English literature [2–8].
Although the majority of PEComas behave in a benign or
indolent fashion, a minority of tumors exhibit aggressive
behavior. The malignant variant may cause diagnostic pit-
falls, particularly in interpretation of biopsy specimens. In* Correspondence: softtissuetumor@163.com
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ing primarily in the femur to broaden the anatomic
spectrum of primary bone PEComas.Case presentation
Clinical presentation
A 47-year-old male presented with a 2-year history of
pain and progressive swelling of his left thigh. Computed
tomography (CT) scan and magnetic resonance imaging
(MRI) of the left lower limb revealed an osteolytic lesion
in the distal femur (Figs. 1a and b), measuring 5.2 ×
3.2 × 2.6 cm in size. The lesion showed destruction of
the cortex with extension into the surrounding skeletal
muscle. Curettage of the lesion was performed which
was initially reported as a clear cell tumor with recom-
mendation for the exclusion of a metastatic clear cell car-
cinoma. No evidence of a primary tumor in any site
elsewhere was identified by subsequent systematic exami-
nations. However, CT scan of the chest revealed multipleis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Radiology. Magnetic resonance imaging scan shows an osteolytic lesion in the distal femur (a). CT scan demonstrates cortical destruction
and extension into adjacent soft tissue (b). Chest CT shows metastatic disease in bilateral lungs (c,d)
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static by CT-guided core needle biopsy (Figs. 1c and d).
The patient was treated with conservative palliative radio-
therapy and systemic chemotherapy. He was alive with the
disease at 3.5 year follow up.
Pathological findings
Histologically, the tumor was composed of plump polyg-
onal cells with abundant clear to palely eosinophilic or
granular cytoplasm arranged in nests that were separated
by a delicate aborizing or sinusoidal-type vasculature
(Figs. 2a and b). The tumor cells showed a moderate to
high degree of hypercellularity and nuclear atypia
(Fig. 2c). A few multinucleated giant cells were also ob-
served. Mitotic figures were readily encountered (5/
50HPF). Occasional atypical mitotic figures were present.
Areas of coagulative tumor necrosis were obvious within
the tumor (Fig. 2d). Immunohistochemically, the tumor
cells were strongly positive for HMB45 (Fig. 3a), PNL2,TFE3 and vimentin. Most tumor cells were also positive for
alpha smooth muscle actin (Fig. 3b). There was weak stain-
ing of CD10 and CD117. CD34 staining clearly delineated
the rich vascular network, highlighting the organoid or si-
nusoidal architecture. The tumor cells were negative for
Melan-A, AE1/AE3, EMA, desmin and S100 protein.Discussions
The first case of primary bone PEComa was described
by Insabato et al. in 2002 which occurred in the tibia of
a 30-year-old male [2]. The presentation of PEComa as a
primary bone lesion is extremely rare. Taking the
current case into account, there are only 11 cases of pri-
mary bone origin. The clinical features of these 11 pri-
mary bone PEComas are summarized in Table 1. The
site of involvement includes right tibia in 3 cases [2, 6],
right fibula in 3 cases [3, 4, 8], vertebral column in 2
cases (7th thoracic and 5th lumbar respectively) [6, 7],
Fig. 2 Histology. Epithelioid cells arranged in nested pattern with delicate arborizing vasculature (×100, a). Sinusoidal-type vasculature in PEComa
(×200, b). Nuclear pleomorphism with multinucleate tumor cells and mitotic activity (×200, c). Area of necrosis present within the tumor (×100, d)
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(current case) in 1 case each. Like PEComas arising in other
sites, primary bone PEComas also occurred in middle-aged
adults with a mean age of 47 years and median age of
39 years (range, 26 to 93 years) respectively. Unlike PEComas
of other sites which tended to have a female predilection,Fig. 3 Immunohistochemistry. HMB45 (EnVision × 100, a). Alpha smooth mprimary bone PEComas were distributed approximately
equally in both sexes. This disparity is possibly due to
the limited number of bone PEComas being reported
thus far. In accordance with the very low frequency of
TSC-associated PEComas, none of the patients with
bone PEComas had association with TSC.uscle actin (EnVision × 100, b)
Table 1 Clinical features of 11 cases of primary bone PEComa
Author/Reference Age (y)/Sex Site Size (cm) Presentation Radiologic features Treatment Follow-up
Insabato et al. [2] 30/M Right proximal tibia 2 Pain Osteolytic with cortical destruction Local resection ANED, 12mo
Torri et al. [5] 28/M Right 6th rib 2 Pain Osteolytic Complete resection ANED, not reported
Righi et al. [4] 92/F Right fibula NA NA NA Local resection NA
Lian et al. [3] 52/F Right mid-shaft fibula 6.3 Progressive swelling Extension through the cortex
forming a soft-tissue mass
Wide excision ANED, 3mo
Yamashita et al.
[6], case 1








39/F Right tibia 6.5 Pain Enhancing mass with areas of
breakthrough of the cortex
forming a soft-tissue mass
RT + Excision ANED,34mo
Yamashita et al.
[6], case 3
48/F Right distal tibia Very small Pain Permeable destructive lesion




Recurred 3 times in
3 y, ANED, 3y






Desy et al. [8], case 1 93/F Right distal fibula NA Progressive pain, swelling Expansile lytic lesion Local resection ANED,2y






Lao et al. (our case) 47/M Left femur 5.2 Pain, progressive swelling Osteolytic mass, destruction of
cortex forming a soft-tissue mass
Curettage + CRT Lung metastases,
AWD, 3.5y
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sented with pain. Three patients were accompanied with
swelling [3, 8], one of whom had a pathologic fracture of
the distal fibula [8]. One patient was accompanied with
bilateral leg weakness because of cord compression [6].
Radiologically, primary PEComas of bone frequently appeared
as osteolytic lesions. In more aggressive cases, destruc-
tion of cortex with forming of soft tissue mass could be
noted [2, 6–8]. On MR imaging, the tumor was usually
hypointense on T1-weighted imaging and hyperintense
on T2-weighted images [6, 8]. In a biopsy-proven malig-
nant PEComa, F-18 FDG PET demonstrated intense hy-
permetabolism [9]. Of note, FDG PET scans were often
negative in patients with benign PEComas and positive
in malgiant PEComas [10]. However, a benign PEComa
of the lungs with extensive FDG uptake has also been
described [11].
Histologically, most bone PEComas were composed of
epithelioid perivascular cells that exhibited characteristic
nesting or organoid arrangement. Two case were com-
posed of both epithelioid and spindle cells [6]. Of 11
cases, 3 were considered to be benign which were also
supported by the clinical outcome [2, 4, 6, 8]. One case
was supposed to have malignant potential based on the
invasion into the surrounding connective tissues and
overexpression of cyclinD1 [5]. The remaining 7 cases
were recognized histologically as fully malignant. Besides
permeative growth pattern, marked nuclear atypia was
present in all 7 cases, necrosis was seen in 2 cases (in-
cluding the current case) [3], and mitotic activity was
noted in 6 cases, ranging from 5/50HPF to 36/50HPF
[6]. Vascular invasion was identified in 2 cases [3, 6]. It
is worthy to note that although most cases of malignant
PEComa fulfilled the morphological criteria for malig-
nancy proposed by Folpe et al. [1], rare example existed
which was not clearly malignant on histological ground,
especially on biopsy specimens [7]. In such instance, the
malignancy was usually betrayed by its aggressive clinical
behaviour.
The major differential diagnosis in the current case in-
cludes metastatic clear cell carcinoma, especially of renal
origin. However, immunohistochemical study ruled out
this possibility as the tumor cells failed to express
epithelial markers. Alveolar soft part sarcoma (ASPS), a
sarcoma characterized by organoid pattern and sinusoidal-
type vasculature, may cause confusion with PEComa. In
particular, both tumors can express TFE3 [4, 12]. The ab-
sence of melanocytic differentiation in ASPS is helpful in
the separation of these two entities. The other lesions that
may enter the differential diagnoses are metastatic malig-
nant melanoma and clear cell sarcoma. In addition to
morphological differences, strong S100 protein and nega-
tive staining of myogenic markers in most melanomas and
clear cell sarcomas (CCS), the presence of specific EWSR1ATF1 fusion transcripts resulting from t (12:22) (q13;
q12) in CCS are helpful features to distinguish the
lesions from PEComa.
It seems that malignant PEComa of bone has a ten-
dency to develop metastatic disease. Of 7 malignant
bone PEComas, four developed metastatic disease, in-
cluding pelvic bone metastases in one case [6], and lung
metastases in other 3 cases (including the current case)
[7, 8]. At present, the optimal therapy for malignant
PEComa remains a challenging practice. The activation
of the mTOR signaling pathway was thought mechanis-
tically to be linked to the development of both TSC-
associated and non-TSC-associated PEComa [13]. Based
on this pathologic mechanism, mTOR inhibitors (siroli-
mus/rapamycin) was applied in small number of cases
and considered to be a rational molecular target for
therapy in malignant PEComa [14]. One patient with a
malignant PEComa of the left acetabulum tried five cy-
cles of temsirolimus with a favorable response of the
suspected pulmonary metastases. However, the patient
passed away eight months postoperatively despite several
months of additional treatment [8].
Conclusions
We have described the clinicopathological and immuno-
histochemical features of a malignant PEComa arising
primarily in the femur of an adult male. Although very
rare, PEComa can present as a primary bone lesion.
Clinical and pathological correlation is mandatory in ar-
riving at the correct diagnosis.
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